Table 1.

Changes in Cardiac Morphology and In Vivo Ventricular Function Induced by Doxorubicin in Vehicle- and Pargyline-Treated Mice

	Vehicle	Doxo	Doxo+Pargyline
BW, g	31.40 ± 0.47	22.38 ± 0.91a	24.28 ± 1.20a
LV mass/BW	4.18 ± 0.25	5.48 ± 0.26b	3.93 ± 0.15c
IVS, cm	0.96 ± 0.02	1.02 ± 0.03	0.94 ± 0.04
LVEDD, cm	3.14 ± 0.06	2.85 ± 0.09	2.66 ± 0.16d
LVESD, cm	1.12 ± 0.02	1.40 ± 0.05b	1.00 ± 0.05c
LVPW, cm	0.9 ± 0.03	1.01 ± 0.03d	0.9 ± 0.03e
Heart rate, bpm	712.00 ± 4.06	587.15 ± 50.67b	646.00 ± 30.71
FS, %	64.27 ± 0.88	51.01 ± 1.09a	62.20 ± 1.38c
EF, %	95.40 ± 0.33	88.14 ± 0.78a	94.51 ± 0.64f

Data are expressed as mean ± standard error of the mean. Vehicle n = 5; Doxo n = 7; Doxo+Pargyline n = 5.

^ap < 0.001 versus Vehicle, ^bp < 0.01 versus Vehicle, ^cp < 0.001 versus Doxo, ^dp < 0.05 versus Vehicle, ^ep < 0.05 versus Doxo, ^fp < 0.01 versus Doxo.

BW, body weight; EF, ejection fraction.; FS, fractional shortening; IVS, interventricular septum; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVmass/BW, left ventricular mass normalized to body weight (expressed as mg of left ventricle/gram of body weight mg/g); LVPW, left ventricular posterior wall.